Ivonescimab's Label Update Impact on Lung Cancer Treatment
Akeso, Inc. (9926.HK) has made significant strides in cancer care with the recent approval of ivonescimab's updated label in China. This first-in-class PD-1/VEGF bispecific antibody has garnered attention due to its remarkable results from the HARMONi-A study. The National Medical Products Administration's endorsement marks a pivotal moment for patients suffering from locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those who have faced challenges after EGFR-TKI therapy.
Significance of the HARMONi-A Study
The HARMONi-A trial stands out as a groundbreaking research initiative. Being the first Phase III immunotherapy study targeting EGFR-TKI-resistant nsq-NSCLC, it sets a precedent by delivering statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). This pivotal trial has established new hope for patients by demonstrating that combinations of immunotherapy and anti-angiogenic treatments can yield exceptional results.
Results That Matter
The final analysis of OS, focusing on a median follow-up of 32.5 months, unveiled some compelling findings. Ivonescimab, when given alongside chemotherapy, proved to substantially enhance overall survival compared to chemotherapy alone. Notably, the combination therapy exhibited a 26% lower risk of death, with the survival advantages growing more pronounced over time. Moreover, it significantly curbed the chances of disease progression or mortality by 54%, extending the median PFS from 4.8 to 7.1 months.
Long-term Safety Profile
As exciting as the efficacy results are, safety remains a top priority. The long-term evaluation of ivonescimab’s safety profile has continued to show a favorable outcome, with no new safety concerns arising. The incidence of common treatment-related adverse events remained comparable between the two treatment groups, assuring both patients and healthcare providers of a tolerable treatment course.
Regulatory Milestones for Ivonescimab
Building on the success from the HARMONi-A study, ivonescimab was granted approval by regulatory authorities in May for its use. Further enhancing its accessibility, it was included in China's National Reimbursement Drug List (NRDL) in November, effective January 1, 2025. This action not only underscores the drug's importance but also ensures that patients have increased access to this therapeutic option.
First-line Treatment Advances
April of the following year marked another victory for ivonescimab with its approval for first-line treatment of PD-L1-positive NSCLC. Subsequently, it secured a spot on the NRDL, reflecting its promise as an effective and well-tolerated therapy. This innovation offers an additional chemotherapy-free option for patients at an early stage, providing hope for a better quality of life.
About Akeso and Its Commitment to Innovation
Founded in 2012, Akeso (HKEX: 9926.HK) has established itself as a leader in the biopharmaceutical sector, focusing on innovative and groundbreaking treatments. Utilizing an integrated R&D innovation system, the company aims to develop best-in-class biological products. Their comprehensive platform supports a robust pipeline of over 50 innovative assets targeting cancer, autoimmune diseases, and metabolic disorders among others.
With 26 candidates currently in clinical trials and 7 new drugs already on the market, Akeso continues to push the boundaries of traditional therapeutics. By combining powerful bi-specific antibody technologies with a commitment to rapid and impactful research, Akeso is on track to becoming a global powerhouse in biopharmaceuticals.
Frequently Asked Questions
What is ivonescimab?
Ivonescimab is a bispecific antibody developed by Akeso that targets PD-1 and VEGF pathways, aimed at treating lung cancer.
What are the main results of the HARMONi-A study?
The HARMONi-A study demonstrated significant improvements in progression-free survival and overall survival for patients treated with ivonescimab.
How does ivonescimab compare to traditional treatments?
Ivonescimab has shown considerable efficacy in patients who have not responded to conventional therapies, offering them a new pathway to survival.
Is ivonescimab safe for patients?
Clinical trials have shown that ivonescimab has a favorable safety profile, with no new safety signals identified in long-term follow-ups.
How can patients access ivonescimab?
Ivonescimab is available through China’s National Reimbursement Drug List, enhancing patient access to this life-saving treatment.
